They treat blood born cancers, B-cell cancers. Blood born cancers make up 10-20% of all cancers. In order to kill the cancer cells, they must kill the b-cells. Once you are willing to kill healthy parts of the body, you have side effects. Most cancers aren't such that you can kill the organs or cells associated with them. You can't for instance target healthy pancreatic antigens. With B-cell cancer, once you've committed to wiping out the healthy B-cell population, you must treat the patient for that. As you may know, many blood born cancers are also less genetically heterogeneous, and thus respond to more therapies. In patients who do not respond, destruction of the healthy B cell population is still a last resort. Kite, Juno and a couple others are fighting over the exact same technology patents, and they are working in a very narrow field. The backers of one of the companies is, if I remember, Jeff Bezos, who sunk a lot into the company. Anyway, they are treating what amounts to a relatively small, but always important group of patients, and they need to get off the ground. It's a shame the 4 or so companies cannot work things out, but I'm glad there is funding available for their research. It could easily be a couple end stage diseases (for those who do not respond to SOC) that otherwise might get overlooked.
News 
Market Data 
Discover 
